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บทคดัยอ่  
การใชอ้นุพนัธอ์นิสลุนิทีใ่หฤ้ทธิต์ลอดเวลา (basal insulin analogs) มคีวามสาํคญั
มากขึน้กบัการควบคมุโรคเบาหวาน ในปจัจบุนัมยีาอนุพนัธอ์นิสลุนิทีอ่อกฤทธิย์าว 
เช่น อินสุลินกลาร์จีน 100 ยูนิต (insulin glargine 100 units; IGla 100U) และ 
อนิสลุนิดเีทอเมยีร ์(detemir insulin) ซึง่ทัง้สองชนิดน้ียงัใหผ้ลสรรีวทิยาทีต่่างจาก
การหลัง่ของอนิสุลนิตามธรรมชาต ิเมื่อใหย้าเหล่าน้ีในขนาดสงูมกัพบว่าใหร้ะดบั
ยาพุ่งสงู และมกัไม่สามารถใหฤ้ทธิค์รอบคลุมตลอด 24 ชัว่โมงได ้ดงันัน้จงึพฒันา
ยา IGla 300U ซึ่งเป็นอนุพันธ์อินสุลินที่เป็นรูปแบบยาค่อยปลดปล่อย ทัง้น้ี 
องคก์ารอาหารและยาของสหรฐัอเมรกิาไดร้บัรอง IGla 300U เมื่อ 25 กุมภาพนัธ ์
2558 เป็นยาทีใ่ช้ได้ทัง้เบาหวานชนิดที ่1 และ 2 โดยใหป้ระสทิธภิาพและความ
ปลอดภยัโดยมคีวามแปรปรวนทางเภสชัพลศาสตรน้์อยและใหฤ้ทธิค์รอบคลุม 24 
ชัว่โมง ทําให้เกิดภาวะน้ําตาลตํ่าค่อนข้างน้อย น้ําหนักเพิ่มค่อนข้างน้อย และ
สามารถปรับขนาดยาได้ง่าย โดยสรุป IGla 300U สามารถใช้เป็นยารักษา
เบาหวานที่มีประสิทธิภาพโดยลดความเสี่ยงต่อภาวะน้ําตาลในเลือดตํ่าและ
น้ําหนกัเพิม่ 
คาํสาํคญั: อนิสลุนิกลารจ์นี, อนิสลุนิออกฤทธิย์าวทีใ่หฤ้ทธิต์ลอดเวลา  
Abstract 
Basal insulin analogs are essential for diabetes management. Currently 
available long-acting insulin (insulin glargine 100 units; IGla 100U) and insulin 
detemir still do not completely mimic physiological insulin secretion. When 
administered with high dose, their pharmacokinetic profile showed a peak 
concentration and a low dose may not be adequate to cover a 24-hour 
duration of action. Insulin glargine 300 units (IGla 300U) is a new basal 
insulin with a slow release formulation. The US Food and Drug Administration 
(FDA) approved IGla 300U in February 25, 2015. It can be used both in type 
1 and type 2 diabetes mellitus. It offers efficacy and safety with less 
pharmacodynamic variability and duration of action over 24 hours, resulting 
in less hypoglycemic episodes, less weight gain and more flexible dosing 
regimen. In summary, IGla 300U would be an effective treatment option for 
diabetes while minimizing risks of hypoglycemia and weight gain.  
Keywords: insulin glargine, ultra-long acting basal insulin   
 
Introduction 
In 2016, World Health Organization (WHO) reported that 
an estimated 422 million adults were living with diabetes in 
2014 compared to 108 million in 1980, indicating the poor 
glycemic control of diabetic patients all around the world.1 
Insulin plays an important role in diabetes management and 
long-acting basal insulins are the standard of care in both type 
1 (T1DM) and type 2 diabetes mellitus (T2DM). Insulin 
glargine (IGla) was a first once-daily, long-acting insulin 
analog which has been introduced in clinical practice for more 
than 10 years to provide required basal insulin. An ideal insulin 
regimen is to provide an optimal glycemic control with limited 
adverse events, and improve the patient’s convenience.  
Unfortunately, current basal insulin options (IGla 100U) 
and insulin detemir (IDet) do not fulfill the main requirements 
of the ideal basal insulin namely flat pharmacodynamic profile 
with low hypoglycemic risk, 24-hours duration of action and 
low inter-individual variability. Such undesirable properties 
could contribute to the fear to initiate insulin therapy because 
of concerns regarding the potential side effects, including 
hypoglycemia, weight gain and the inconvenient use of insulin. 
Therefore, additional consideration for new insulin 
formulations is required.  
IGla 300U was a new formulation of IGla 100U which is 
designed to provide the same number of insulin units of IGla 
100U with a third of its volume. It has more flat-line, prolonged 
pharmacokinetic and pharmacodynamic profile, longer 
duration of action and less variation in blood glucose control 
than IGla 100U. The less pronounced peak of action could 
result in a more gradual reduction of plasma glucose, reducing 
the risk of hypoglycemia while achieving the glycemic 
control.2,3 The purpose of this review is to discuss about the 
development of IGla 300U and provide an insight of its 
potential role in diabetes treatment.  
 
Formulation, Structure and 
Mechanism of Action  
 
Insulin glargine (21A-Gly-31B-32B-Di-Arg-human insulin) is 
a recombinant human insulin analog which is modified from 
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human insulin by replacing the asparagine amino acid at 
position A21 with glycine and two arginine amino acids are 
added to the C-terminus of the B-chain. IGla 300U is a new 
formulation of insulin glargine and available in the market as 
TOUJEO U-300, 1.5 mL. It is three times more concentrated, 
resulting in a two-thirds lower subcutaneous spheric depot 
with a surface area reduced by 50% as compared with IGla 
100U. This results in a slower and prolonged absorption of 
insulin. It is less soluble in neutral pH and more soluble in 
acidic pH 4. After subcutaneous injection, IGla 300U functions 
essentially as a prodrug in subcutaneous tissue, with the 
majority of activity from its metabolites.4,5  
 
Pharmacokinetic and 
Pharmacodynamic Properties  
 
A multi-dose, two-treatment, two-period, two-sequence 
crossover study was conducted in T1DM by giving once-daily 
subcutaneous administrations of either 0.4 (cohort 1) or 0.6 
units/kg (cohort 2) IGla 300U for 8 days in one treatment 
period and 0.4 units/kg Gla-100 for 8 days in the other. At 
steady state, pharmacokinetic profile of IGla 300U was more 
constant and evenly distributed over 24 hours compared with 
IGla 100U and lasted longer. The supporting data were at the 
time to 50% of area under the serum insulin and glucose 
infusion rate time curves from time 0 to 36 hours post-dosing. 
Maintenance of tight blood glucose control (≤ 105 mg/dL) was 
approximately 5 hours longer with IGla 300U. At steady state, 
IGla 300U has a terminal half-life of 19 hours with a prolonged 
duration of activity (well beyond 24 hours). Steady state is 
reached after 3 - 4 days.6 It has the same metabolism as IGla 
100U and is metabolized into active metabolite such as M1 
(Gly A21) and M2 (Gly A21, des-Thr B 30). M1 was the 
principal active moiety and it takes 4 days to reach the steady 
state concentration of M1 metabolite.7 A multi-dose crossover 
study of IGla 300U 0.4U/kg, with six once-daily injections, in 
T1DM, showed that it has a low within-day variability with the 
peak-to-trough ratio of insulin concentration profile being < 2 
and both swing and peak-to-trough fluctuation being < 1. It 
also has a high day-to-day reproducibility. The between-day 
within-subject coefficients of variation for total systemic 
exposure, with an area under the curve (AUC) from time 0 to 
24 hours after dosing of 17.4% (95% confidence interval (or 
CI): 15 – 21%) and a maximum insulin concentration of 33.4% 
(95% CI: 28 – 41%).8 Two single-dose studies conducted in 
Japan and Europe with T1DM patients showed that serum 
glargine concentration and glucose infusion rate developed 
more gradually with a constant and prolonged action with IGla 
300U than with IGla 100U.8,9 The times to reach 50% glargine 
exposure and insulin activity were longer for all IGla 300U 
doses (0.4 U or 0.6 U or 0.9 U/kg) than IGla 100U during 36 
hours clamp period. In the Japanese study, median T50%-INS-
AUC0-36,h was 14 hrs for 0.4 U/kg IGla 100U vs. 17 hrs for 0.4 
U/kg, 18 hrs for 0.6 U/kg of IGla 300U.9 In the European study, 
median T50%-INS-AUC0-36,h was 13 hr for 0.4 U/kg IGla 100U vs. 
15 hrs for 0.4 U/kg, 17 hrs for 0.6 U/kg and 19 hrs for 0.9 
U/kg of  IGla 300U.8  
IGla 300U also allows flexible dosing (24  up to 3 hours) 
and does not compromise efficacy and safety profiles in 
people with T2DM. Although recommendation for a flexible-
dosing schedule with IGla 300U was not included in the 
package insert, a substudy suggested that occasional 
flexibility (up to 3 hours) in dosing time is reasonable because 
there was no difference in efficacy and safety outcome 
between flexible and fixed dosing groups.10 In T1DM, IGla 
300U injected either in the morning or the evening provided 
similar overall glucose control and percentage time in target 
sensor glucose range (4.4 - 7.8 mmol/L) vs. IGla 100U. There 
was also less hypoglycemia and mean glucose profile for all 
subjects with less glucose excursion and lower within- and 
between-day glucose variability. It is indicated that IGla 300U 
can be given any time of the day.11 In summary, IGla 300U 
has flat, stable and ultra-long-acting pharmacokinetic 
properties in both T1DM and T2DM with its modified slow-
release formulation.  
 
Starting Dose, Dose Adjustment 
and Switching Therapy    
   
For T2DM insulin naïve patients, the recommended 
starting dose for IGla-300U is 0.2U/kg of body weight once 
daily. For T1DM insulin naive patients, 0.2 - 0.4 U/kg can be 
calculated as an initial total daily insulin dose and 
approximately 1/3 to 1/2 of the total daily insulin dose should 
be administered as basal insulin. The remainder is 
administered as short acting insulin, divided between each of 
the daily meals. Dose adjustment should be individualized. 
The dose of IGla 300U can range from 1 to 80 U per one 
injection. Dose should be titrated not more frequently than 
every 3 - 4 days to minimize the risk of hypoglycemia. For 
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switching therapy, unit-to-unit basis transition can be 
considered for patients receiving once daily long-acting or 
intermediate-acting insulin. For patients with twice daily 
isophane (NPH) regimen, the recommended starting dose of 
IGla 300U was 80% of the total daily NPH dose, given once 
daily to minimize the risk of hypoglycemia. Blood glucose 
should be monitored frequently in the first week of therapy and 
the dose of IGla 300U should be titrated accordingly. Other 
glucose lowering therapies should also be monitored and 
adjusted individually to minimize the risk of hypoglycemia. The 
maximum glucose lowering effect of a dose of IGla 300U may 
take 5 days to fully manifest and the first dose may be 
insufficient to cover metabolic needs in the first 24 hours of 
use.12  
    
Special Populations  
  
For elderly patients, in controlled clinical studies, 30 of 304 
IGla 300U treated T1DM patients (9.8%) and 327 of 1242 IGla 
300U treated T2DM patients (26.3%) were 65 years or older. 
Among these elderly, 2% of patients with T1DM and 3% of 
those with T2DM were 75 years or older. No overall 
differences in effectiveness and safety were observed in 
subgroup analysis of the age groups. However, caution should 
be taken when giving it to geriatric patients to avoid 
hypoglycemia. 
For renal and hepatic impairment, there were no available 
clinical studies conducted for IGla 300U. However, as with all 
insulin products, glucose monitoring should be intensified and 
the dose should be adjusted on an individual basis in patients 
with renal or hepatic impairment.12 
   
Efficacy 
A series of EDITION studies were conducted to examine 
the efficacy and safety of IGla 300U. For T2DM patients, four 
EDITION studies (EDITION-1, EDITION-2, EDITION-3 and 
EDITION-JP 2) which included patients not achieving glycemic 
control with basal bolus meal time insulin, basal insulin plus 
oral antidiabetic drugs. The primary endpoint in all studies was 
non-inferiority for A1C change from baseline to month 6 and 
the main secondary endpoint in the trials of people with T2DM 
was the percentage of participants with at least 1 nocturnal 
confirmed or severe hypoglycemic event from week 9 to 
month 6. According to such outcome, nocturnal meant 
midnight to 5:59 a.m., while confirmed hypoglycemia was 
defined as a blood glucose of ≤ 70 mg/dL. In addition, severe 
hypoglycemia was defined by the American Diabetes 
Association definition. All EDITION studies of T2DM showed 
a consistent efficacy of similar HbA1C reductions by IGla 
300U, ranging from -0.45% to -1.42%, compared with -0.55% 
to -1.46% by IGla 100U. The data are summarized in Table 
1. The patient level meta-analysis of EDITION 1,2,3 studies 
also confirmed that mean change in glycated hemoglobin was 
comparable between IGla 300U and IGla 100U, i.e., -1.02 with 
a standard error of 0.03% for both regimens, and a least 
square mean (LSM) difference of 0.00 with 95% CI of -0.08 to 
0.07, for both regimens.13 At the end of the 6-month study, a 
dosing increase was seen in IGla 300U when compared with 
IGla 100U as found in EDITION-1 study: 0.97 vs. 0.88 
U/kg/day, LSM difference 0.09 U/kg/day (95% CI: 0.062-
0.124), in EDITION-2 study: 0.92 vs. 0.84 U/kg/day, LSM 
difference 11 U/day (95% CI: 8-14), and in EDITION-3 study: 
0.62 U/kg/day vs. 0.53 U/kg/day. This may be due to a slight 
decrease in bioavailability related to longer subcutaneous 
resistance time with exposure to tissue peptidase.14-16   
For Type 1 DM, currently available data are derived from 
only 2 studies (EDITION-4 and EDITION-JP 1) which used 
IGla 100U as a comparator of IGla 300U. Both studies found 
non-inferiority in HbA1C reduction between IGla 300U and 
IGla 100U. Estimated treatment difference (ETD) of the 
HbA1C reduction between IGla 300U and IGla 100U was 
0.04% (95% CI -0.10 to 0.19) in EDITION-4 study and 0.13% 
(95% CI -0.03 to 0.29) in EDITION-JP 1 study. The data are 
shown in Table 1. 
     
Safety 
Hypoglycemia   
Six-month open-label extension studies of EDITION-1, -2, 
and -3 and EDITION-JP 2 showed that the use of IGla 300U 
resulted in a significant reduction in the nocturnal 
hypoglycemia in T2DM when compared with IGla 100U. The 
risk ratios (RRs) were 0.78 (95% CI 0.68-0.89), 0.71 (95%    
CI 0.58-0.86), 0.71 (95% CI 0.58-0.86), and 0.62 (95% CI 
0.44-0.88) for EDITION-1, -2, -3, and EDITION-JP 2, 
respectively.
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 Table 1  Efficacy of IGla 300U on HbA1C and FPG reduction.    
Study Population, concomitant 
therapy, duration 
Treatment arm  
Baseline 
mean 
HbA1C 
% (SD)  
Mean 
HbA1C  
reduction 
% (SE)  
ETD (%) for 
HbA1C  
reduction  
(95% CI) 
Baseline 
mean 
FPG  
(mmol/L)  
(SD)  
Mean 
FPG reduction 
(mmol/L) 
(SE)  
ETD  
(mmol/L)  
for FPG 
(95% CI)  
EDITION-1  
(2014)14  
- T2DM 
- Basal + mealtime 
insulin ± MET  
- 6 months 
- IGla 300U (N = 404)  
- IGla 100U (N = 403) 
- 8.15 (0.78) 
- 8.16 (0.77) 
- 0.83 (0.06) 
- 0.83 (0.06) 
- 0.00 (-0.11, 0.11)  - 8.8 (2.9)  
- 8.9 (2.9) 
-1.48 (SD = 3.11)  
-1.69 (SD = 3.21) 
- NA 
EDITION-2  
(2014)15 
 
- T2DM 
- Basal insulin + OADs 
(discontinued SU) 
- 6 months 
- IGla 300U (N = 404)  
- IGla 100U (N = 407)  
- 8.26 (0.86) 
- 8.22 (0.77) 
- 0.57 (0.09) 
- 0.56 (0.09) 
-0.01 (-0.14, 0.12)  - 8.24 (2.97) 
- 7.89 (2.67) 
- 1.14 (SD = 3.42) 
- 1.06 (SD = 3.02) 
- 0.19 (-0.15, 0.52) 
EDITION-3  
(2015)16  
- T2DM 
- Insulin naïve, 
(discontinued SU) 
- 6 months 
- IGla 300U (N = 432)  
- IGla 100U (N = 430)  
- 8.49 (1.04) 
- 8.58 (1.07) 
- 1.42 (0.05) 
- 1.46 (0.05) 
- 0.04 (-0.09, 0.17)  - 9.93 (2.86) 
- 10.21 (2.90) 
- 3.41 (0.10) 
- 3.8 (0.11) 
- 0.39 (0.10, 0.68) 
EDITION-JP 2 
(2016)20  
 
- T2DM Japanese 
- Basal insulin + OADs, 
- 6 months 
- IGla 300U (N = 121)  
- IGla 100U (N = 120)  
- 7.99 (0.72) 
- 8.06 (0.77) 
- 0.45 (0.06)  
- 0.55 (0.06)  
- 0.10 (-0.08, 0.27)  - 7.7 (2.1)  
- 7.4 (1.9)  
-1.21 (0.16) 
- 1.25 (0.16) 
- 0.04 (-0.40, 0.49) 
EDITION-4  
(2015)18  
- T1DM 
- Basal + mealtime insulin 
- 6 months  
- IGla 300U (N = 274)  
- IGla 100U (N = 275)  
- 8.11 (0.77) 
- 8.14 (0.79)  
- 0.42 (SD =  0.98) 
- 0.44 (SD = 0.72) 
- 0.04 (-0.10, 0.19)  - NA  
- NA 
- NA 
- NA 
- NA 
- NA 
EDITION-JP 1 
(2016)19 
 
- T1DM Japanese 
- Basal + mealtime 
insulin 
- 6 months  
- IGla 300U (N = 122)  
- IGla 100U (N = 121)  
- 8.06 (0.64) 
- 8.07 (0.74)  
- 0.30 (0.06) 
- 0.43 (0.06)  
- 0.13 (-0.03, 0.29)  - NA 
- NA  
- 0.75 (0.4)  
- 1.2 ( 0.4)  
- 0.4 (-0.6, 1.4) 
 
Abbreviations: T2DM: type 2 diabetes mellitus, T1DM: type 1 diabetes mellitus, IGla 300U: insulin glargine 300U, IGla 100U: insulin glargine 100U, SD: standard deviation, SE: standard Error, OADs: oral antidiabetic drugs, NA; not 
available, SU: sulphonylurea, MET: metformin, ETD: estimated treatment difference.  
 
The percentage of people experiencing severe 
hypoglycemia and hypoglycemia at any time of the day over 
the six-month period was also lower with IGla 300U (Table 2). 
In addition, a network meta-analysis was conducted to 
compare the efficacy and safety of IGla 300U with other basal 
insulins including NPH insulin, pre-mixed insulin, insulin 
detemir and insulin degludec. The analysis found that IGla 
300U was associated with a significantly lower nocturnal 
hypoglycemia rate when compared with NPH (RR = 0.18; 95% 
Credible interval (CrI): 0.05 to 0.55), and with premixed insulin 
(RR = 0.36; CrI: 0.14 to 0.94), and no significant difference 
when it was compared with detemir (RR = 0.52; CrI: 0.19 to 
1.36) or degludec (RR = 0.66; CrI: 0.28 to 1.50).17  
In EDITION-4 study, during the 6-month period, rate of 
one or more confirmed (FPG ≤ 70 mg/dl) or severe 
hypoglycemic events was similar both for IGla 300U and IGla 
100U, 93% and 94%, respectively, among T1DM patients. 
Equal percentage of nocturnal hypoglycemia was also found 
in both groups (69% vs. 70%). However, for the first 8 weeks 
of the study, there was a reduced rate of nocturnal confirmed 
or severe hypoglycemia (FPG ≤ 70 mg/dL) in IGla 300U group 
(RR = 0.69, 95% CI: 0.53 - 0.91).18  
 
 Table 2  Safety of IGla 300U in confirmed hypoglycemia and 
nocturnal hypoglycemia.   
Study,  
study arm  
Confirmed or severe hypoglycemia†  Severe 
hypoglycemia, 
baseline to 
month 6  
Nocturnal, baseline 
to  
week 8 
Nocturnal, 
week 9 to 
month 6 
Nocturnal, baseline 
to  
month 6 
Any time of  
the day, baseline 
to month 6 
EDITION-1 (2014) 14  
- IGla 300U (N = 404)  
- IGla 100U (N = 403) 
- 26.2% 
- 33.3% 
- RR = 0.79 
(95% CI: 0.64 - 0.98)  
- 36.1% 
- 46.0% 
- RR = 0.79 
(95% CI: 0.67 - 0.93)  
- 44.6% 
- 57.5% 
- RR = 0.78 
(95% CI: 0.68 - 0.89)  
- 81.9% 
- 87.8% 
- RR = 0.93 
(95%CI: 0.88-0.99) 
- 5.0% 
- 5.7%  
- RR = 0.87 
(95% CI: 0.48-1.55) 
EDITION-2 (2014)15 
- IGla 300U (N = 404)  
- IGla 100U (N = 407) 
- 13.2% 
- 24.6% 
- RR = 0.53 
(95% CI: 0.39 - 0.72) 
- 21.6% 
- 27.9% 
- RR = 0.77 
(95% CI: 0.60 - 0.97) 
- 28.3% 
- 39.9% 
- RR = 0.71 
(95% CI: 0.58 - 0.86) 
- 70.0% 
- 77.3% 
- RR = 0.90 
(95% CI: 0.83-0.98) 
- 1.0% 
- 1.5% 
- NA 
EDITION-3 (2015)16  
- IGla 300U (N = 432)  
- IGla 100U (N = 430)  
- 7.4% 
- 10.0% 
- RR = 0.74 
(95% CI: 0.48 - 1.13) 
- 15.4% 
- 17.1% 
- RR = 0.9 
(95% CI: 0.67 - 1.22) 
- 17.9% 
- 23.5% 
- RR = 0.76 
(95% CI: 0.59 - 0.99) 
- 46.2% 
- 52.5% 
- RR = 0.88 
(95% CI: 0.77 - 1.01) 
- 0.9% 
- 0.9% 
- NA 
EDITION-JP 2 (2016)20  
- IGla 300U (N = 121)  
- IGla 100U (N = 120) 
- 13.3% 
- 16.7% 
- RR = 0.83 
(95% CI: 0.45 - 1.52) 
- 25.4% 
- 43.7% 
- RR = 0.58 
(95% CI: 0.40 - 0.85) 
- 28.3% 
- 45.8% 
- RR = 0.62 
(95% CI: 0.44 - 0.88) 
- 65.0% 
- 76.7% 
- RR = 0.86 
(95% CI: 0.73 - 1.01) 
- 2.5% 
- 1.7% 
- RR = 1.25 
(95% CI: 0.31 - 4.98) 
EDITION-4 (2015)18  
- IGla 300U (N = 274)  
- IGla 100U (N = 275) 
- 46.7% 
- 57.1% 
- RR = 0.82 
(95% CI: 0.7 - 0.96) 
- 59.1% 
- 55.6% 
- RR = 1.06 
(95% CI: 0.92 - 1.23) 
- 68.6% 
- 70.2% 
- RR = 0.98 
(95% CI: 0.88 - 1.09) 
- 93.1% 
- 93.5% 
- RR = 1 
(95% CI: 0.95 - 1.04) 
- 6.6% 
- 9.5% 
- RR = 0.71 
(95% CI: 0.41 - 1.24) 
EDITION-JP 1 (2016)19  
- IGla 300U (N = 122)  
- IGla 100U (N = 121) 
- 43.4% 
- 61.2% 
- RR = 0.71 
(95% CI: 0.56 - 0.91)  
- 61.7% 
- 73.7% 
- RR = 0.84 
(95% CI: 0.70 - 1.00) 
- 68.9% 
- 81.0% 
- RR = 0.85 
(95% CI: 0.73 - 0.99) 
- 96.7% 
- 97.5% 
- RR = 0.99 
(95% CI: 0.95 - 1.04) 
- 5.7% 
- 9.9% 
- RR = 0.58 
(95% CI: 0.24 - 1.42) 
Abbreviation: T2DM: type 2 diabetes mellitus, T1DM: type 1 diabetes mellitus, IGla 300U: insulin glargine 300U, IGla 100U: insulin glargine 100U, RR: relative risk comparing 
IGla 300U to IGla 100U.   
 * People experiencing ≥ 1 hypoglycemic event (safety population), SU: Sulphonylurea.  
 † confirmed hypoglycemia = ≤ 3.9 mmol/L or ≤ 70 mg/dl.   
 
Weight gain 
IGla 300U was also associated with less weight gain 
compared with IGla 100U in EDITION studies. In EDITION-1, 
weight gain is similar in both groups. In EDITION-2, -3 and -
4, lower weight gain was found in IGla 300 group compared 
with IGla 100U, although not significant in EDITION-3 study 
(Table 3).  
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 Table 3  Change in weight in IGla 300U versus IGla-100U 
in EDITION Phase 3 trials.  
Study 
Least Square Mean Change (kg) 
IGla 300 U IGla 100 U P-value 
EDITION-115 0.9 0.9 NA 
EDITION-216 0.08 (SD = 3.45) 0.66 (SD = 3.01) 0.015 
EDITION-317 0.49 (95% CI: 0.14 to 0.83)  0.71 (95% CI: 0.36 to 1.06) NS 
EDITION-418 0.5 (SE = 3.3)  1.0 (SE = 3.2) 0.037 
EDITION-JP 119  -0.1 (SE = 0.2) 0.4 (SE = 0.2) 0.035 
EDITION-JP 220  -0.6 (SE = 0.2) 0.4 (SE = 0.2) 0.0003 
Abbreviations: IGla 300U: insulin glargine 300U/ml, IGla 100U: insulin glargine 100U/ml, NA: data not available, NS: not significant, 
SD: standard deviation, SE: standard error.  
 
Conclusion  
Overall, according to the existing data, IGla 300U was a 
new formulation of IGla 100U which has a more flat and stable 
pharmacokinetic profile than IGla 100U. Although IGla 300U 
has the similar efficacy of HbA1C reduction with IGla 100U, it 
offers a benefit of less hypoglycemia and less weight gain.  
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